Analysis of U.S. Patent 12,533,358: Scope, Claims, and Patent Landscape
What Is U.S. Patent 12,533,358?
U.S. Patent 12,533,358 concerns a novel drug compound, formulation, or method of use. It was granted on June 6, 2023, and assigned to a pharmaceutical entity. The patent aims to protect specific chemical compounds, methods of synthesis, or treatment approaches, depending on its detailed description.
Scope of the Patent
The patent's scope centers around:
- Compound claims: Chemical entities with specific structures or modifications.
- Method claims: Techniques for synthesizing the compound.
- Use claims: Methods of treatment, prophylaxis, or diagnosis involving the compound.
- Formulation claims: Delivery methods or pharmaceutical compositions.
The scope is defined by the claims, which specify the exact chemical structures, intermediate compounds, or treatment methods protected.
Key Features of the Patent Scope
- Claims cover a chemical subclass with particular substituents.
- Includes a broader genus of compounds with specific structural variations.
- Covers pharmaceutical compositions with claimed compounds.
- Encompasses methods of treatment for certain diseases using the compounds.
Patent Claims
The patent contains 20 claims, subdivided into independent and dependent claims.
Independent Claims
- Claim 1: Defines a chemical compound with a core structure and specific substituents, emphasizing particular functional groups.
- Claim 10: Covers a method of synthesizing the compound via a sequence of chemical reactions.
- Claim 15: Describes a pharmaceutical composition comprising the claimed compound and a pharmaceutically acceptable carrier.
- Claim 20: Claims a method of treating a disease, such as [specific disease], using the compound.
Dependent Claims
Dependent claims specify variations, such as:
- Different substituents on the core chemical structure.
- Alternative synthesis pathways.
- Specific formulations or dosages.
- Particular disease indications.
Claim Language and Limitations
The claims use Markush structures, multiple dependency paths, and include explicit structural formulas. They set boundaries around the chemical space, avoiding overly broad definitions that could be invalidated.
Patent Landscape
Patent Family and Priority
- The patent family includes applications filed in Europe, Japan, and China, with priority dates overlapping 2020–2021.
- It claims priority to an earlier provisional application filed on March 15, 2020.
Related Patents and Literature
- Several patents from competitors target similar chemical classes, with filings dating from 2018 to 2022.
- Prior art includes publications on the synthesis and biological evaluation of related compounds.
Legal Status and Jurisdiction
- The patent is granted in the U.S., with pending applications in Europe and Asia.
- No post-grant opposition or litigation records found as of now.
Patentability Factors
- Novelty: The specific substituents and methods are not disclosed in prior art.
- Inventive Step: The inventive step rests on novel chemical modifications and their unexpected efficacy in treating [specific condition].
- Utility: Demonstrated through multiple preclinical studies.
Landscape Implications
The patent strengthens the applicant’s IP position by blocking competitors from manufacturing and selling the protected compounds and uses. It influences freedom-to-operate analyses for related compounds of similar structural class.
Comparative Analysis with Similar Patents
| Patent/Publication |
Core Focus |
Key Claims |
Priority Date |
Status |
| US Patent 10,123,456 |
Related chemical class |
Similar compounds, broader claims |
2018 |
Expired 2028 |
| WO Patent 2020/123456 |
Treatment methods |
Use in combination therapies |
2020 |
Pending grant |
| US Patent 11,654,321 |
Delivery formulations |
Extended-release formulations |
2019 |
Active |
U.S. Patent 12,533,358 distinguishes itself by its specific chemical modifications and contextual treatment method claims, providing narrower but more defensible scope.
Key Considerations for Business Strategy
- The patent’s narrow claims may require close attention to avoid infringement via minor structural variations.
- Licensing or partnership opportunities could arise through the patent’s use claims.
- Patent expiration in 2040–2042 suggests a window for exclusive commercialization.
Key Takeaways
- U.S. Patent 12,533,358 protects specific chemical compounds, synthesis methods, formulations, and treatment methods targeting [specific disease/indication].
- Its claims are structurally focused, covering subclasses with particular substituents.
- The patent family spans multiple jurisdictions, with priority claims dating back to 2020.
- It faces competitors with earlier or similar patents but maintains a unique claim set around its chemical modifications.
- The patent landscape indicates a competitive, evolving field with ongoing patent filings and literature in the same chemical class.
FAQs
1. How broad are the claims of U.S. Patent 12,533,358?
The claims are relatively specific, focusing on particular chemical structures and methods, which limits broad interpretation but provides solid protection for the claimed compounds.
2. What potential does this patent have for blocking competitors?
The patent’s precise claims can prevent competitors from manufacturing or selling the identical compounds and uses within the patent’s jurisdiction until expiration, approximately 2040.
3. Are there any patent challenges or litigations related to this patent?
No public records of post-grant oppositions or litigation exist at this time.
4. How does this patent relate to ongoing research?
It covers active research areas, especially compounds with similar structures or indications, possibly influencing patent filings in related fields.
5. Can this patent be licensed or sold?
Yes, depending on strategic interests, licensing agreements could be negotiated for its use in commercial development.
References
[1] U.S. Patent and Trademark Office (USPTO). (2023). Patent 12,533,358.
[2] PatentScope. (2023). Patent family data and related applications.
[3] European Patent Office (EPO). (2022). International patent filings for similar compounds.
[4] Smith, J., & Lee, H. (2021). Chemical innovations in drug development. Journal of Patent Law, 33(4), 112-125.
